BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 8638211)

  • 1. Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism.
    Tal A; Graves L
    South Med J; 1996 Jun; 89(6):637-40. PubMed ID: 8638211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism.
    Jansson S; Tisell LE; Lindstedt G; Lundberg PA
    Surgery; 1991 Sep; 110(3):480-6. PubMed ID: 1845370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical effects from treatment with bisphosphonate and surgery in patients with primary hyperparathyroidism.
    Jansson S; Morgan E
    World J Surg; 2004 Dec; 28(12):1293-7. PubMed ID: 15517486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Disodium pamidronate (APD) in therapy of hypercalcemia in primary hyperparathyroidism].
    Kotzmann H; Svoboda T; Bernecker P; Clodi M; Woloszczuk W; Niederle B; Waldhäusl W; Luger A
    Wien Klin Wochenschr; 1994; 106(13):422-5. PubMed ID: 8091766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The efficacy and safety of intravenous bisphosphonates in the treatment of primary hyperparathyroidism complicated by hypercalcemia crisis].
    Han GY; Wang O; Xing XP; Meng XW; Lian XL; Guan H; Ye W; Xia WB; Li M; Jiang Y; Hu YY; Liu HC; Cui QC
    Zhonghua Nei Ke Za Zhi; 2009 Sep; 48(9):729-33. PubMed ID: 20079207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium.
    van Breukelen FJ; Bijvoet OL; Frijlink WB; Sleeboom HP; Mulder H; van Oosterom AT
    Calcif Tissue Int; 1982 Jul; 34(4):321-7. PubMed ID: 6814719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pamidronate treatment in patients with tumor-associated hypercalcemia: pharmacological effects and pharmacokinetics.
    Oiso Y; Tomita A; Hasegawa H; Ariyoshi Y; Niinomi M; Yamamoto M; Takano T; Sakiyama N
    Endocr J; 1994 Dec; 41(6):655-61. PubMed ID: 7704089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy.
    Fraser WD; Logue FC; Gallacher SJ; O'Reilly DS; Beastall GH; Ralston SH; Boyle IT
    Bone Miner; 1991 Feb; 12(2):113-21. PubMed ID: 1849762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
    Nussbaum SR; Younger J; Vandepol CJ; Gagel RF; Zubler MA; Chapman R; Henderson IC; Mallette LE
    Am J Med; 1993 Sep; 95(3):297-304. PubMed ID: 8368227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperparathyroidism due to eutopic PTH secretion from an ectopic intrathymic parathyroid cyst.
    Hoi WH; Leow MK; Sule A; Lee HY; Mmed TA; Tay JC
    Ann Thorac Cardiovasc Surg; 2011; 17(5):511-3. PubMed ID: 21881376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors predicting the acute effect of pamidronate on serum calcium in hypercalcemia of malignancy.
    Gallacher SJ; Fraser WD; Logue FC; Dryburgh FJ; Cowan RA; Boyle IT; Ralston SH
    Calcif Tissue Int; 1992 Dec; 51(6):419-23. PubMed ID: 1333351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypercalcemia associated with tertiary hyperparathyroidism managed conservatively with pamidronate in a hemodialysis patient.
    Czosnowski LM; Hudson JQ; Canada RB
    Am J Med Sci; 2009 Apr; 337(4):300-1. PubMed ID: 19365180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diphosphonates in the treatment of hypercalcemia].
    Delmas PD; Meunier PJ
    Rev Med Interne; 1984 Nov; 5(4):363-6. PubMed ID: 6240753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone.
    Gucalp R; Theriault R; Gill I; Madajewicz S; Chapman R; Navari R; Ahmann F; Zelenakas K; Heffernan M; Knight RD
    Arch Intern Med; 1994 Sep; 154(17):1935-44. PubMed ID: 8074597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.
    Walls J; Ratcliffe WA; Howell A; Bundred NJ
    Br J Cancer; 1994 Jul; 70(1):169-72. PubMed ID: 8018531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating PTH and PTHrP levels before and after treatment of tumor induced hypercalcemia with Pamidronate Disodium (APD).
    Grill V; Murray RM; Ho PW; Santamaria JD; Pitt P; Potts C; Jerums G; Martin TJ
    J Clin Endocrinol Metab; 1992 Jun; 74(6):1468-70. PubMed ID: 1592895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation and treatment of hypercalcemia.
    Mundy GR
    Hosp Pract (Off Ed); 1994 Jun; 29(6):79-84; discussion 84-6. PubMed ID: 8207113
    [No Abstract]   [Full Text] [Related]  

  • 18. Aminohydroxypropylidene diphosphonate treatment of hypercalcemic crisis due to primary hyperparathyroidism.
    Evans RA
    Aust N Z J Med; 1987 Feb; 17(1):58-9. PubMed ID: 3476049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of 1,25(OH)2D production by hypercalcemia in osteitis fibrosa cystica: influence on parathyroid hormone secretion and hungry bone disease.
    Brossard JH; Garon J; Lepage R; Gascon-Barré M; D'Amour P
    Bone Miner; 1993 Oct; 23(1):15-26. PubMed ID: 8274876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.
    Gucalp R; Ritch P; Wiernik PH; Sarma PR; Keller A; Richman SP; Tauer K; Neidhart J; Mallette LE; Siegel R
    J Clin Oncol; 1992 Jan; 10(1):134-42. PubMed ID: 1727915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.